Lv1
70 积分 2022-01-11 加入
Complete pathological remission after neoadjuvant ensartinib in patients with locally advanced lung adenocarcinoma and with CTLC-ALK and ALK-DHX8 rearrangements
1天前
已完结
The Proposed 9th Edition TNM Classification of Lung Cancer
2个月前
已完结
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer
2个月前
已完结
Osimertinib-Related QTc Prolongation: Real-World Incidence and Impact of Drug Dosing on Recurrence Risk
2个月前
已完结
The Risk and Reversibility of Osimertinib-related Cardiotoxicity in a Real-World Population
2个月前
已完结
Abstract CT170: D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156)
2个月前
已关闭
EP07.05-02 NEOEAST: A Phase II Study of Ensartinib as Neoadjuvant Therapy for Stage II-IIIB ALK-rearranged Non-small Cell Lung Cancer
3个月前
已完结
Rezivertinib versus Gefitinib as First-line Therapy for EGFR-mutated Locally Advanced or Metastatic NSCLC Patients (REZOR): A Multicenter, Double-blinded, Randomized Phase 3 Study
5个月前
已关闭
Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas Following Complete Lobectomy
5个月前
已完结
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC)
5个月前
已完结
皖公网安备34019202002308
